Exelixis
EXEL
#1725
Rank
S$12.88 B
Marketcap
$45.11
Share price
-1.16%
Change (1 day)
44.84%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : S$0.92 Billion

According to Exelixis's latest financial reports the company's total liabilities are S$0.92 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31S$0.89 B14.63%
2022-12-31S$0.78 B42.54%
2021-12-31S$0.54 B60.52%
2020-12-31S$0.34 B26.88%
2019-12-31S$0.26 B46.16%
2018-12-31S$0.18 B-62.81%
2017-12-31S$0.49 B-32.42%
2016-12-31S$0.73 B9.51%
2015-12-31S$0.66 B15.62%
2014-12-31S$0.57 B4.54%
2013-12-31S$0.55 B6.63%
2012-12-31S$0.51 B32.51%
2011-12-31S$0.39 B-48.35%
2010-12-31S$0.75 B6.59%
2009-12-31S$0.71 B8.73%
2008-12-31S$0.65 B39.33%
2007-12-31S$0.46 B0.56%
2006-12-31S$0.46 B1.92%
2005-12-31S$0.45 B16.8%
2004-12-31S$0.39 B17.72%
2003-12-31S$0.33 B17.79%
2002-12-31S$0.28 B39.83%
2001-12-31S$0.20 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$80.87 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$82.44 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
S$98.88 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
S$103.62 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
S$112.95 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$146.52 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
S$171.98 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
S$69.39 M-92.52%๐Ÿ‡บ๐Ÿ‡ธ USA
S$98.09 M-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA